| 000 | 01623 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516114059.0 | ||
| 264 | 0 | _c20130429 | |
| 008 | 201304s 0 0 eng d | ||
| 022 | _a1873-569X | ||
| 024 | 7 |
_a10.1016/j.jdermsci.2012.09.002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMiyake, Tomomi | |
| 245 | 0 | 0 |
_aEpidermal-type FABP is a predictive marker of clinical response to systemic treatment and ultraviolet therapy in psoriatic skin lesions. _h[electronic resource] |
| 260 |
_bJournal of dermatological science _cDec 2012 |
||
| 300 |
_a199-202 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdalimumab |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers _xmetabolism |
| 650 | 0 | 4 |
_aFatty Acid-Binding Proteins _xblood |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPsoriasis _xblood |
| 650 | 0 | 4 |
_aSkin _xmetabolism |
| 650 | 0 | 4 | _aUltraviolet Therapy |
| 700 | 1 | _aOgawa, Eisaku | |
| 700 | 1 | _aMikoshiba, Asuka | |
| 700 | 1 | _aKobayashi, Aya | |
| 700 | 1 | _aHosoe, Hiroaki | |
| 700 | 1 | _aKashiwabara, Shoji | |
| 700 | 1 | _aUhara, Hisashi | |
| 700 | 1 | _aOwada, Yuji | |
| 700 | 1 | _aOkuyama, Ryuhei | |
| 773 | 0 |
_tJournal of dermatological science _gvol. 68 _gno. 3 _gp. 199-202 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jdermsci.2012.09.002 _zAvailable from publisher's website |
| 999 |
_c22161662 _d22161662 |
||